Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 5/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039978 | 0.90 | EPHX2 (0.37) | EPHX2KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL9914311 | 0.90 | EPHX2 (0.37) | EPHX2KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL10039980 | 0.88 | EPHX2 (0.36) | EPHX2KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL15928439 | 0.81 | EPHX2 (0.36) | EPHX2KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL15928635 | 0.80 | EPHX2 (0.36) | EPHX2KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL15928443 | 0.80 | EPHX2 (0.36) | EPHX2KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL15928437 | 0.79 | EPHX2 (0.35) | EPHX2KMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL7936516 | 0.78 | CTSK (0.38) | CTSKHDAC4HDAC1CTSS | |
| SCHEMBL28700425 | 0.77 | KMT2A (0.36) | KMT2AALDH1A1MEN1MAPK1HDAC4 | |
| SCHEMBL5229523 | 0.76 | MEN1 (0.41) | EPHX2KMT2AALDH1A1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655321-B1 | PURIFICATION OF PRECURSOR COMPOUND BY CRYSTALLISATION | GE HEALTHCARE LTD (GB) | 2017-02-15 | — | — | EP | disclosed |
| US-9238596-B2 | Process simplification for precursor compound | GE HEALTHCARE LIMITED (GB) | 2016-01-19 | — | — | US | disclosed |
| US-9061977-B2 | Purification of precursor compound by crystallisation | GE HEALTHCARE LIMITED (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20130274507-A1 | PROCESS SIMPLIFICATION FOR PRECURSOR COMPOUND | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130267730-A1 | PURIFICIATION OF PRECURSOR COMPOUND BY CRYSTALLISATION | GE HEALTHCARE LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2007001958-A2 | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274507-A1 | PROCESS SIMPLIFICATION FOR PRECURSOR COMPOUND | PAICS, FGB, FIP1L1 | EPHX2 1406/4885KMT2A 3638/4885ALDH1A1 1462/4885 |
| US-20130267730-A1 | PURIFICIATION OF PRECURSOR COMPOUND BY CRYSTALLISATION | RFC1, PAICS, RFC2 | EPHX2 2847/4885KMT2A 4579/4885ALDH1A1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.